Actinium Pharmaceuticals, Inc. Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock

NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the pricing of an underwritten public offering of an aggregate 4,444,444 shares of its common stock and warrants to purchase an aggregate of 3,333,333 shares of the Company's common stock at a combined price to the public of $4.50. The shares of common stock and warrants will be issued separately. The warrants will be exercisable for a period of 4 years following the issuance thereof at an exercise price of $6.50 per share. The warrants will be certificated, and will be delivered to the investors by physical delivery at the closing. There is no established public trading market for the warrants and Actinium does not expect a market to develop in the future. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 666,666 shares of common stock and warrants to purchase 499,999 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about February 11, 2015, subject to customary closing conditions.

Help employers find you! Check out all the jobs and post your resume.

Back to news